Fernandes Catarina Lopes, Silva Diogo J, Mesquita Alexandra
Medical Oncology Department, Pedro Hispano Hospital, 4464-513 Matosinhos, Portugal.
Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Cancers (Basel). 2023 Dec 23;16(1):87. doi: 10.3390/cancers16010087.
Human epidermal growth factor 2 (HER-2)-positive breast cancer represents 15-20% of all breast cancer subtypes and has an aggressive biological behavior with worse prognosis. The development of HER-2-targeted therapies has changed the disease's course, having a direct impact on survival rates and quality of life. Drug development of HER-2-targeting therapies is a prolific field, with numerous new therapeutic strategies showing survival benefits and gaining regulatory approval in recent years. Furthermore, the acknowledgement of the survival impact of HER-2-directed therapies on HER-2-low breast cancer has contributed even more to advances in the field. The present review aims to summarize the newly approved therapeutic strategies for HER-2-positive breast cancer and review the new and exploratory HER-2-targeted therapies currently under development.
人表皮生长因子2（HER-2）阳性乳腺癌占所有乳腺癌亚型的15%-20%，具有侵袭性生物学行为，预后较差。HER-2靶向治疗的发展改变了该病的进程，对生存率和生活质量产生了直接影响。HER-2靶向治疗的药物研发是一个成果丰硕的领域，近年来有众多新的治疗策略显示出生存获益并获得了监管批准。此外，对HER-2导向治疗对HER-2低表达乳腺癌生存影响的认识，进一步推动了该领域的进展。本综述旨在总结新批准的HER-2阳性乳腺癌治疗策略，并回顾目前正在研发的新型和探索性HER-2靶向治疗。
